Depletion of CD4 +CD25 + regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model

Clinical and Experimental Immunology

Volumn 159, Issue 1, 2010, Pages 93-99

  Hong, H ^a,b   Gu, Y ^c   Zhang, H ^b   Simon, A K ^b,e   Chen, X ^a   Wu, C ^d   Xu, X N ^b   Jiang, S ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c First Affiliated Hospital   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

galactosylceramide; Anti tumour immunity; CD4 +CD25 + regulatory T cells; Innate; Natural killer T cells

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; AXXORA; INTERLEUKIN 2 RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; LUNG METASTASIS; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; T CELL DEPLETION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; GALACTOSYLCERAMIDES; IMMUNITY, CELLULAR; INTERFERON-GAMMA; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NATURAL KILLER T-CELLS; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY;

EID: 70749146017     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.04018.x     Document Type: Article

References (21)

1. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002 2 : 557 568.
2. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008 133 : 775 787.
3. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005 23 : 877 900.
4. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003 21 : 483 513.
5. Kawano T, Cui J, Koezuka Y et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997 278 : 1626 1629.
6. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009 9 : 28 38.
7. Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. Adv Cancer Res 2008 101 : 277 348.
8. Wang HY, Lee DA, Peng G et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004 20 : 107 118.
9. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008 8 : 523 532.
10. Salama P, Phillips M, Grieu F et al. FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009 27 : 186 192.
11. Giannopoulos K, Schmitt M, Kowal M et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008 20 : 677 682.
12. Sonabend AM, Rolle CE, Lesniak MS. The role of regulatory T cells in malignant glioma. Anticancer Res 2008 28 : 1143 1150.
13. Liyanage UK, Goedegebuure PS, Moore TT et al. Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother 2006 29 : 416 424.
14. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999 163 : 5211 5218.
15. Viehl CT, Moore TT, Liyanage UK et al. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol 2006 13 : 1252 1258.
16. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007 25 : 297 336.
17. Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 2002 196 : 119 127.
18. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol 2001 Chapter 20: Unit 20 2.
19. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992 52 : 1399 1405.
20. Goldman B, DeFrancesco L. The cancer vaccine roller coaster. Nat Biotechnol 2009 27 : 129 139.
21. Chen L, Huang TG, Meseck M, Mandeli J, Fallon J, Woo SL. Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol Ther 2007 15 : 2194 2202.